Pheochromocytoma and glucoregulation disorders.

Area of Science:

• Endocrinology
• Oncology
• Metabolic Disorders

Background:

• Pheochromocytomas (PCCs) are rare tumors producing excess catecholamines, leading to severe cardiovascular risks.
• PCCs can also disrupt glucose regulation, causing impaired glucose tolerance and diabetes mellitus.
• The impact of surgical tumor removal on these glycemic abnormalities is not fully understood.

Purpose of the Study:

• To evaluate the effect of adrenalectomy on glycemic status in patients with pheochromocytoma.
• To determine the rate of resolution for diabetes and glucose intolerance post-surgery.

Main Methods:

• Retrospective analysis of 23 patients who underwent adrenalectomy for pheochromocytoma between 2009 and 2018.
• Data collection focused on preoperative glycemic status (diabetes, glucose intolerance) and follow-up after one year.
• Correlation of tumor characteristics and patient BMI with glycemic outcomes.

Main Results:

• 60.78% of patients presented with concurrent glycemic disorders (26% diabetes, 34.78% glucose intolerance).
• One year post-adrenalectomy, 57.14% of patients with diabetes or glucose intolerance showed complete resolution.
• Large, symptomatic tumors and elevated BMI were associated with higher preoperative diabetes prevalence and persistence.

Conclusions:

• Adrenalectomy can effectively reverse or improve glycemic abnormalities in patients with pheochromocytoma.
• Screening for glucose regulation disorders is essential upon pheochromocytoma diagnosis, especially in patients with risk factors like elevated BMI.
• Early diagnosis and treatment of pheochromocytoma are vital for managing associated metabolic complications.